Triazolopyrimidine Crystalline Forms Solubility and Residual Solvent Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing pharmaceutical composition of N-((5-Fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine hydrochloride, known as Compound X, faces challenges with low aqueous solubility, variable crystallinity, and residual organic solvent contamination, particularly isopropanol, which affects its bioavailability and storage stability.
Innovation Solution
Development of crystalline forms, specifically Forms A, H A, and H B, using solvent combinations like EtOH/water and acetone/water, which enhance solubility, reduce residual solvent content, and improve crystallinity, allowing for consistent production and increased bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If isopropanol is used as the manufacturing solvent for Compound X, then the compound can be produced, but residual isopropanol contamination occurs affecting bioavailability and storage stability
Solution Approach 1:
The patent changes the solvent parameter from isopropanol to ethanol/water or acetone/water mixtures. This parameter change resolves the contradiction by eliminating residual isopropanol contamination while maintaining manufacturability. The new solvent system produces Compound X with reduced residual solvent levels, improving bioavailability and storage stability without compromising the manufacturing process.
Solution Approach 2:
The patent employs a disposable solvent system where ethanol/water or acetone/water are used and completely removed through evaporation and drying. These solvents serve their purpose during manufacturing and are then eliminated, leaving no harmful residues. This approach replaces the problematic isopropanol system with a cleaner, more suitable solvent that can be fully removed.
2Ease of manufacture
If conventional solid forms of Compound X are used, then production is simplified, but low aqueous solubility and variable crystallinity reduce bioavailability
Solution Approach 1:
The patent changes the physical state parameter of Compound X from conventional solid forms to specifically defined crystalline forms (Forms A, HA, and HB). Each form has defined crystal structure characteristics that ensure consistent crystallinity and improved aqueous solubility. This parameter change resolves the contradiction by providing reliable bioavailability through controlled crystallinity while maintaining production simplicity.
Solution Approach 2:
The patent creates composite crystalline structures with specific molecular arrangements and intermolecular interactions. The crystalline forms represent organized composite structures of Compound X molecules in specific spatial configurations, which provide both consistent crystallinity and improved solubility properties while maintaining manufacturing ease.
3Reliability
If multiple solid forms (polymorphs) are considered for Compound X, then solubility and stability can be optimized, but selection complexity increases
Solution Approach 1:
The patent segments the solid forms of Compound X into three distinct, well-defined crystalline forms (Forms A, HA, and HB), each with specific characterization parameters. This segmentation resolves the contradiction by providing clear, discrete options with defined properties, making selection straightforward based on specific solubility and stability requirements rather than dealing with undefined polymorphic variability.
Solution Approach 2:
The patent defines specific parameter ranges for each crystalline form (XRPD patterns, DSC transitions, solubility values) that serve as selection criteria. By establishing these parameter specifications, the patent simplifies the selection process - manufacturers can choose the appropriate form by matching their needs to the defined parameter profiles of Forms A, HA, or HB, reducing complexity while ensuring optimized performance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms of Compound X achieve improved bioavailability, dose-proportional exposure, and reduced residual solvent levels, addressing the issues of low solubility and variable crystallinity, thereby enhancing its therapeutic efficacy and storage stability.
Implementation Method 1
Development of crystalline forms, specifically Forms A, H A, and H B, using solvent combinations like EtOH/water and acetone/water, which enhance solubility, reduce residual solvent content, and improve crystallinity
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.